Ertugliflozin for Type 2 Diabetes

被引：2
|
作者：
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2018年 / 319卷 / 23期
关键词：
D O I：
10.1001/jama.2018.5840
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2434 / 2435
页数：2
相关论文
共 50 条
  • [31] Incidence of urinary tract infections in patients with type 2 diabetes receiving ertugliflozin, placebo or active comparator
    Hickman, M. A.
    Patel, S.
    Lauring, B.
    Terra, S. G.
    Johnson, S.
    Huyck, S.
    Mancuso, J. P.
    [J]. DIABETOLOGIA, 2018, 61 : S306 - S306
  • [32] Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
    Sam Miller
    Tania Krumins
    Haojin Zhou
    Susan Huyck
    Jeremy Johnson
    Gregory Golm
    Steven G. Terra
    James P. Mancuso
    Samuel S. Engel
    Brett Lauring
    [J]. Diabetes Therapy, 2018, 9 : 253 - 268
  • [33] Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Khan, Parvej
    Venkatesh, Shubhashree
    Parveen, Rizwana
    Mishra, Pinki
    Jain, Seema
    Agarwal, Nidhi
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) : 2199 - 2210
  • [34] Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
    Miller, Sam
    Krumins, Tania
    Zhou, Haojin
    Huyck, Susan
    Johnson, Jeremy
    Golm, Gregory
    Terra, Steven G.
    Mancuso, James P.
    Engel, Samuel S.
    Lauring, Brett
    [J]. DIABETES THERAPY, 2018, 9 (01) : 253 - 268
  • [35] Evaluation of fractures, bone mineral density and bone biomarkers in patients with type 2 diabetes receiving ertugliflozin
    Masiukiewicz, U.
    Hickman, A.
    Frederich, R.
    Patel, S.
    Gallo, S.
    Lauring, B.
    Terra, S. G.
    Johnson, S.
    Huyck, S.
    Mancuso, J. P.
    [J]. DIABETOLOGIA, 2018, 61 : S306 - S307
  • [36] Ertugliflozin effectively improves glycaemic control as monotherapy in patients with type 2 diabetes: the VERTIS MONO trial
    Terra, S.
    Davies, M. J.
    Frias, J.
    Derosa, G.
    Darekar, A.
    Focht, K.
    Golm, G.
    Johnson, J.
    Saur, D.
    Dagogo-Jack, S.
    [J]. DIABETOLOGIA, 2016, 59 : S346 - S346
  • [37] Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM)
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Huyck, Susan
    Wu, Larry
    Mancuso, James P.
    Terra, Steven
    Lauring, Brett
    [J]. DIABETES, 2018, 67
  • [38] Assessment of Adverse Renal Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin
    Patel, Shrita M.
    Hickman, Mary A.
    Frederich, Robert
    Lauring, Brett
    Terra, Steven
    Johnson, Susan L.
    Huyck, Susan
    Mancuso, James P.
    [J]. DIABETES, 2018, 67
  • [39] Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
    Derosa, Giuseppe
    Maffioli, Pamela
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1637 - 1640
  • [40] Efficacy and Safety of Ertugliflozin in Hispanic/Latino Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)
    Liu, Jie
    Tarasenko, Lisa
    Ellison, Misoo C.
    Pong, Annpey
    Huyck, Susan
    Mancuso, James P.
    Terra, Steven G.
    Gantz, Ira
    [J]. DIABETES, 2019, 68
12345